Project Grant R01CA282475
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$696K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding for researchers at the University of California, San Francisco (UCSF) to develop a new technology called "Structural Surfaceomics" to identify novel immunotherapy targets based on cancer-specific conformations of surface proteins. The $550,255 award, with a performance period from August 1, 2024 to July 31, 2029, supports two key objectives: 1) advancing the Structural...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $540,288 to the University of Florida to research the role of bacterial-derived small molecules in improving response to immune checkpoint inhibitor (ICI) treatment for non-small cell lung cancer (NSCLC). The key products/services to be delivered include: Defining the functional impact of the bacterial metabolite BAC429 on experimental NSCLC, including its immunostimulatory effects...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $563,233 to The Medical University of South Carolina to conduct research aimed at overcoming immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives are to: 1) determine how the sphingosine kinase 2 (SPHK2)-mediated sphingosine-1-phosphate (S1P) axis induces an immunosuppressive MDSC phenotype, 2) elucidate how SPHK2-S1P...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $676,006 to The Regents of the University of California, San Francisco to develop and test non-invasive imaging strategies to identify mechanisms of resistance to immunotherapy. The key products and services to be delivered include: Utilizing PET imaging to measure granzyme B, which contributes to response, and neutrophil levels in the tumor, which contribute to...
This National Cancer Institute Project Grant award for $809,234 is funding research to discover potent and selective inhibitors of the histone methyltransferase SUV39H1 for the treatment of cancer. The overall objective is to develop these SUV39H1 inhibitors as novel stand-alone antitumor drugs and immunomodulators. Specifically, the project aims to: 1) identify selective SUV39H1 hit scaffolds from a high-throughput screen of 320,000 compounds, 2) convert a clinical-grade SUV39H2 inhibitor...
This Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), aims to determine whether targeting the PSGL-1 immune checkpoint can promote the development and maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade therapy. The $674,996 award to the Sanford Burnham Prebys Medical Discovery Institute will investigate the role of PSGL-1 in regulating T cell exhaustion and differentiation, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679.00 to The Institute For Cancer Research to conduct research on targeting the DHX9 protein to trigger viral mimicry and enhance immunotherapy responsiveness in small cell lung cancer (SCLC). The key objectives are to: 1) Determine the role of DHX9 in inducing double-stranded RNAs and RNA-DNA hybrids that can activate antiviral signaling and compromise genome stability in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an engineered prodrug therapy that leverages tumor-associated proteases to selectively deliver potent cytotoxins to cancer cells. The proposed research aims to define the mechanisms of action of this novel anti-cancer strategy, and determine the efficacy, pharmacokinetics, and pharmacodynamics of combining this prodrug therapy with standard-of-care chemotherapy for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,881 to Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The key objectives are to: Elucidate the mechanisms governing the effectiveness of new IgG antibodies engineered to penetrate cancer cells and neutralize mutated oncogenic drivers like KRAS. This will involve selecting a lead candidate antibody for clinical...
This $1,960,529 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a comprehensive research initiative at the University of California, Los Angeles (UCLA) to investigate the role of adenosine signaling in pancreatic cancer and evaluate the impact of a CD73 inhibitor in combination with neoadjuvant chemotherapy and immunotherapy. The key objectives are to: 1) Evaluate the effects of CD73 inhibition on tumor adenosine metabolism,...